Compounds > 1-arabinofuranosylcytosine-5--stearylphosphate

1-arabinofuranosylcytosine-5--stearylphosphate and Anemia

1-arabinofuranosylcytosine-5--stearylphosphate has been researched along with Anemia* in 1 studies

Trials

1 trial(s) available for 1-arabinofuranosylcytosine-5--stearylphosphate and Anemia

Article	Year
[Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:12 Twenty-three patients with hepatocellular carcinoma (HCC) were enrolled in this cooperative study conducted in Hirosaki University Hospital. They were treated with YNK-01, a prodrug of cytarabine for oral administration. YNK-01 was given for 2 weeks and repeated every 4 weeks for as long as possible. There were 13 patients with NC, 10 with PD, and no PR. Among NC cases, 5 patients were maintained with NC for longer than 6 months. The main side effects of YNK-01 were anemia, leukopenia, thrombocytopenia, and symptoms of the alimentary tract (nausea, anorexia, diarrhea, etc), but no severe side effects over Grade 3 were observed. Topics: Administration, Oral; Aged; Anemia; Anorexia; Antineoplastic Agents; Arabinonucleotides; Carcinoma, Hepatocellular; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Thrombocytopenia	1998

Article

Year

[Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma].

Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:12

Twenty-three patients with hepatocellular carcinoma (HCC) were enrolled in this cooperative study conducted in Hirosaki University Hospital. They were treated with YNK-01, a prodrug of cytarabine for oral administration. YNK-01 was given for 2 weeks and repeated every 4 weeks for as long as possible. There were 13 patients with NC, 10 with PD, and no PR. Among NC cases, 5 patients were maintained with NC for longer than 6 months. The main side effects of YNK-01 were anemia, leukopenia, thrombocytopenia, and symptoms of the alimentary tract (nausea, anorexia, diarrhea, etc), but no severe side effects over Grade 3 were observed.

Topics: Administration, Oral; Aged; Anemia; Anorexia; Antineoplastic Agents; Arabinonucleotides; Carcinoma, Hepatocellular; Cytidine Monophosphate; Drug Administration Schedule; Female; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Thrombocytopenia

1998